The Company will participate on China Pharma-Biotech Panel
TAI'AN, Shandong, China, Sept. 10 /PRNewswire-Asia/ -- China Biologic Products, Inc. (OTC Bulletin Board: CBPO) ("China Biologic," or the "Company"), one of the leading plasma-based pharmaceutical companies in the People's Republic of China ("PRC"), operating through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co. Ltd. ("Taibang") and Chongqing Dalin Biologic Technologies Co., Ltd. ("Dalin") and its equity investment in Xi'an Huitian Blood Products Co., Ltd. ("Huitian"), today announced that the Company's management team will attend the upcoming Susquehanna International Group of Companies ("SIG") 3rd Annual Beijing Management Summit, and the Company's CEO, Mr. Colin Zhao, and newly appointed Director of Research and Development, Dr. Vincent Xie, will participate on the China Pharma-Biotech Panel at the conference.
The 3rd Annual Beijing Management Summit is a two-day conference that brings together executives from public and private companies based in China and other emerging Asian economies. The event will showcase leading companies in the Chinese Consumer, Health Care, Internet, and Technology sectors, as well as companies in the IT Services/Outsourcing and Financial Technologies sectors. The event format will consist of one-on-one meetings and company presentations.
The date and location of China Biologic's one-on-one meetings and the China Pharma-Biotech Panel at the SIG 3rd Annual Beijing Management Summit are as follows:
Date: September 16 - 17, 2009
Location: The Grand Hyatt Beijing Hotel
1 East Chang An Avenue
Beijing 100738
Panel Schedule: China Pharma-Biotech Panel
September 16, 2009
1:05-2:10 PM Beijing Time
Drawing Room IV
China Biologic will be available for one-on-one meetings with analysts and portfolio managers during the summit. Interested parties and investors who wish to meet with China Biologic's management may contact vivian.chen@ccgir.com, phone +1-(646) 701-7445, or contact SIG institutional sales directly. Participation in the SIG 3rd Annual Beijing Management Summit is by invitation only.
About China Biologic Products, Inc.
China Biologic Products, Inc. (the "Company"), through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co. Ltd. and Chongqing Dalin Biologic Technologies Co., Ltd, and its equity investment in Xi'an Huitian Blood Products Co., Ltd., is currently the largest non-state-owned plasma-based biopharmaceutical company in China. The Company is a fully integrated biologic products company with plasma collection, production and manufacturing, research and development, and commercial operations. The Company's plasma-based biopharmaceutical products are irreplaceable during medical emergencies, and are used for the prevention and treatment of various diseases. It sells its products to hospitals and other healthcare facilities in China.
For more information, please contact:
Company Contact:
Mr. Y. Tristan Kuo
Chief Financial Officer
China Biologic Products, Inc.
Tel: +86-538-6202206
Email: IR@chinabiologic.com
Web: http://www.chinabiologic.com
Investor Relations Contact:
Mr. Crocker Coulson, President
CCG Investor Relations
Tel: +1-646-213-1915 (NY office) or
Mr. Gary Chin
Tel: +1-646-213-1909
Email: crocker.coulson@ccgir.com
Web: http://www.ccgirasia.com
